capadenoson
Small moleculeexperimental
Clinical trial activity
2 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Jan 1, 2008 (NCT00568945)
Timeline
2000s
- Jan 1, 2008
Earliest Phase 2 Sponsor(trial)
Indications
Mechanism of action
- Adenosine A1 receptorPARTIAL AGONIST
ADORA1 partial agonist
Chemistry & pharmacology
Loading structure…
SMILES
N#Cc1c(N)nc(SCc2csc(-c3ccc(Cl)cc3)n2)c(C#N)c1-c1ccc(OCCO)cc1- Mol. weight
- 520.04 g/mol
- Lipinski Ro5
- 2 violation(s)
- Rule of 3
- No
- Chirality
- Achiral Molecule
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL3235279 ↗
Also known as
- bay 68-4986
- bay 68-4986
- bay-684986
- bay-684986
- bay-68-4986
- capadenoson
- capadenoson
- capadenoson
- capadenoson
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT00518921 | Phase 2 | Mar 1, 2008 | Bayer |
| NCT00568945 | Phase 2 | Jan 1, 2008 | Bayer |
Showing 2 of 2 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bayer | For profit | 2 | 2 | 1 | 2008 |
1 organizations
Page 1 / 1